Navigation Links
Hologic Announces Third Quarter Fiscal 2011 Operating Results
Date:8/1/2011

nths EndedJune 26, 2010EARNINGS PER SHAREGAAP earnings per share- Diluted

$
.49$
.28Adjustments to net income (as detailed below)

0.430.59Non-GAAP adjusted earnings per share- Diluted

$
.92

(1)$
.87

(1)NET INCOMEGAAP net income

$
29,581$
74,161Adjustments:Amortization of intangible assets  

175,320171,299Non-cash interest expense relating to convertible notes

54,43854,418Non-cash loss on convertible notes exchange

29,891-Gain on sale of intellectual property, net

(84,502)-Acquisition-related costs

4,052796Fair value write up of acquired inventory sold

3,298-Contingent consideration

(1,432)-Litigation settlement adjustments

45012,500Restructuring and divestiture charges

-696Income tax effect of reconciling items

(66,845)

(2)(85,194)

(3)Non-GAAP adjusted net income

$
244,251$
228,676EBITDANon-GAAP adjusted net income

$
244,251$
228,676Interest expense, net, not adjusted above

29,97742,453Provision for income taxes

123,044128,631Depreciation expense

51,03851,026Adjusted EBITDA

$
448,310$
450,786EXPLANATORY NOTES:(1) Non-GAAP adjusted earnings per share was calculated based on 264,114 and 261,463 weighted average diluted shares outstanding for the nine months

ended June 25, 2011 and June 26, 2010, respectively.(2) To reflect an estimated annual effective tax rate of 33.5% on a non-GAAP basis.(3) To reflect an estimated annual effective tax rate of 36.0% on a non-GAAP basis.Future Non-GAAP Adjustments: Future GAAP EPS may be affected by changes in ongoing assumptions and judgments relating to the Company's acquired businesses, and may also be affected by nonrecurring, unusual or unanticipated charges, expenses or gains, all of which are excluded in the calculation of non-GAAP adjusted EPS as described in this press release. It is therefore not practicable t
'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CardioVascular Institute enrolled the first patient in Pennsylvania ... in a trial assessing the safety and effectiveness ... main artery of the leg. The new stent allows for ... stent fracture or re-narrowing after the stent is placed. ... the BioMimics 3D Stent System and will enroll 280 subjects ...
(Date:8/27/2015)...  Lightwave Logic, Inc. (OTCQB: LWLG), a technology ... Generation Photonic Devices and Non-Linear Optical Polymer Materials ... data communications and optical computing, announced today that ... to the Company,s Board of Directors. ... is widely recognized with wide-ranging experience across many ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... Probody™ therapeutics for the treatment of cancer, today ... a member of the company,s Board of Directors, ... formerly led immuno-oncology at Eli Lilly and AstraZeneca, ... the first FDA approved checkpoint inhibitor, at Bristol-Myers ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... May 7, 2012  AssureRx Health, Inc. today announced ... the growing number of children and adults diagnosed ... pharmacogenomic test can assist clinicians with important medication ... individual patients tolerate ADHD medications. ...
...  BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, ... announced the completion of a randomized, controlled trial ... product.  ActiPatch uses pulsed electromagnetic field therapy to ... injured tissue. A double blind, ...
Cached Medicine Technology:AssureRx Health Launches Personalized Medicine Test for ADHD 2AssureRx Health Launches Personalized Medicine Test for ADHD 3BioElectronics' ActiPatch Reduces Muscle Soreness in Runners 2
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... ... 27, 2015 , ... Banc Intranets recently entered into a strategic ... both Johnson City, Tenn.-based firms to work synergistically to promote similar products to the ... caters to organizations in the financial, commercial and services sectors. The software, which is ...
(Date:8/27/2015)... ... 2015 , ... Susan Harris and the team at LifeStream Health ... pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is ... the vaginal tissue, revitalizing cells so they make more collagen, an essential component in ...
(Date:8/27/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and Innovation, ... Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , Ms. ...
(Date:8/27/2015)... ... 2015 , ... Standifer Insurance Group, a full service insurance ... joint charity drive with the Meadow View Elementary School in Alabaster. , A ... many lack the simple supplies necessary for a productive scholastic career. In partnering ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3
... people seeking active participation in their communities has led researchers to ... engagement can now be considered a distinct retirement role, according to ... (Volume 48, Number 3). , The authors ... at least one day per week that directly impact the ...
... hours for participants in phase II trial , , ... drug called pegloticase lowered levels of uric acid in ... in most patients. , That,s the conclusion of a ... Savient Pharmaceuticals, the company that,s developing the drug. ...
... Trim Holdings,Inc. (Amex: ZTM ) announced today ... private placement subscription agreements pursuant to which we,sold ... for an,aggregate offering price of $2,370,000. Each of ... consists of a $100,000 24-month,senior secured promissory note ...
... overwhelmingly positive, PORTLAND, Ore., Sept. 3 ... doctor to others, according to a,popular online survey ... A,"Member Feedback" feature on the site allows Regence ... providers, including,physicians, dentists, other health care professionals and ...
... Amsterdam, September 3, 2008 A recent study (doi:10.1016/j.clim.2008.06.009) ... of the Clinical Immunology Society (CIS), describes a new ... human cells. The report demonstrates the characterization of specific ... providing information about the role these cells might play ...
... new survey by Medical Economics details surprising statistics on earnings and ... in wages for many doctors accompanied by a decrease in patient ... ... 2008 -- A newly-released 2008 Medical Economics survey focusing on earnings ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: